From Concept to Practice: The Recent History of Preterm Delivery Prevention. Part II: Subclinical Infection and Hormonal Effects

ABSTRACT

Under the new cervical insufficiency postulate, the final common pathway theoretically may be influenced by multiple interventions including not only cerclage, but also antibiotics, anti-inflammatory drugs, or progesterone. Since the late 1970s, accumulating evidence has implicated intrauterine infection as a cause of preterm labor. The use of antimicrobial therapy for the prevention of preterm delivery (PTD), although plausible and appealing, has remained largely ineffective so far. A decade of antimicrobial intervention trials to prevent infection-mediated PTD has had disappointing results. Several randomized clinical trials have assessed the role of bacterial vaginosis (BV) treatment in prevention of PTD. The inconsistent results of these trials suggest that other processes, possibly immunomodulation, may be important. Additional factors, still unidentified, pertaining to infectious agent virulence or host immune response modulation, may be responsible for the increased risk of PTD in only a small subset of pregnant women with BV. Even a particular genetic susceptibility was proposed as an intervening factor in the correlation between BV and PTD. Autocrine, paracrine, and endocrine processes in the fetal-placental-uterine unit may contribute to the premature activation of parturitional mechanisms. Progesterone has been used in an attempt to prevent PTD since the 1970s, but the evidence accumulated until the 1990s was fraught by mixed results, and was based mostly on underpowered studies with variable eligibility criteria, including history of spontaneous abortion as an indication for treatment. Two recent randomized, controlled clinical trials restimulated the interest in progesterone supplementation, suggesting that progesterone treatment may influence favorably the rate of preterm delivery, as well as perinatal mortality and morbidity. A major impediment in accepting progesterone as the magic bullet in the prevention of PTD is that its mechanism of action is less well understood than that of all the other prophylactic measures discussed in this review. The optimal formulation, route of administration, dose, and gestational age at initiation have yet to be established. Our ability to quantify prospectively the risk of PTD in a given patient is limited. Moreover, there are limited evidence-based strategies available for prevention of PTD, reflecting our incomplete understanding of the nature of preterm labor. Although an effective instrument in PTD prevention is still elusive, the studies conducted so far have led to a shift in our understanding of cervical insufficiency, infection-mediated PTD, and hormonal influences in human parturition.

KEYWORDS

Preterm delivery - prevention - bacterial vaginosis - subclinical infection - progesterone

REFERENCES

• 1 Hillier S L, Martius J, Krohn M A et al.. A case-control study of chorioamnion infection and histologic chorioamnionitis in prematurity.  N Engl J Med. 1988;  319 972-978
• 2 McGregor J A, French J I, Jones W et al.. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.  Am J Obstet Gynecol. 1994;  170 1048-1060
• 3 Mays J K, Figuerioa R, Shah J et al.. Amniocentesis for selection before rescue cerclage.  Obstet Gynecol. 2000;  95 652-655
• 4 Jeffcoat M K, Geurs N C, Reddy M S et al.. Periodontal infection and preterm birth: results of a prospective study.  J Am Dent Assoc. 2001;  132 875-880
• 5 Goldenberg R L, Hauth J C, Andrews W W. Intraucterine infection and preterm delivery.  N Engl J Med. 2000;  342 1500-1507
• 6 Reid G, Bocking A. The potential for probiotics to prevent bacterial vaginosis and preterm labor.  Am J Obstet Gynecol. 2003;  189 1202-1208
• 7 Gray R H, Wabwire-Mangen F, Kigozi G et al.. Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda.  Am J Obstet Gynecol. 2001;  185 1209-1217
• 8 Lockwood C, Senyel A, Dische R et al.. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery.  N Engl J Med. 1991;  325 669-674
• 9 Burrus D R, Esnest J C, Veille J C. Fetal fibronectin, interleukin-6, and C-reactive protein are useful in establishing prognostic subcategories of idiopathic preterm labor.  Am J Obstet Gynecol. 1995;  173 1258-1262
• 10 Andrews W W, Sibai B M, Thom E A et al.. Randomized clinical trial of metronidazole plus erythromycin to prevent spontaneous preterm delivery in fetal fibronectin-positive women.  Obstet Gynecol. 2003;  101 847-855
• 11 Stevens D L, Bryant A E, Hackett S P. Antibiotic effects on bacterial viability toxin production, and host response.  Clin Infect Dis. 1995;  20 S154-S157
• 12 Kenyon S L, Taylor D J, Tarnow-Mordi W et al.. Broad-spectrum antibiotics for spontaneous preterm labour: the ORACLE II randomised trial.  Lancet. 2001;  357 989-994
• 13 King J, Flenady V. Prophylactic antibiotics for inhibiting preterm labour with intact membranes. Cochrane Library, issue 1. Oxford, United Kingdom; Update Software 2003
• 14 Andrews W, Goldenberg R, Hauth J et al.. Interconceptional antibiotics to prevent spontaneous preterm birth (SPTB): a randomized trial [abstract].  Am J Obstet Gynecol. 2003;  189 S57
• 15 Flynn C A, Helwig A L, Meurer L N. Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis.  J Fam Pract. 1999;  48 885-892
• 16 Leitich H, Bodner-Adler B, Brunbauer M et al.. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis.  Am J Obstet Gynecol. 2003;  189 139-147
• 17 Sobel J D. Vaginitis.  N Engl J Med. 1997;  337 1896-1903
• 18 Goldenberg R L, Iams J D, Mercer B M et al.. The preterm prediction study: the value of new vs. standard risk factors in predicting early and all spontaneous preterm births.  Am J Public Health. 1998;  88 233-238
• 19 Newton E R, Piper J, Peairs W. Bacterial vaginosis and intra-amniotic infection.  Am J Obstet Gynecol. 1997;  176 672-677
• 20 McGregor J A, French J I, Parker R et al.. Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation.  Am J Obstet Gynecol. 1995;  173 157-167
• 21 Ralph S G, Rutherford A J, Wilson J D. Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study.  BMJ. 1999;  319 220-223
• 22 Llahi-Camp J M, Rai R, Ison C et al.. Association of bacterial vaginosis with a history of second trimester miscarriage.  Hum Reprod. 1996;  11 1575-1578
• 23 Watts D H, Krohn M A, Hillier S L et al.. Bacterial vaginosis as risk factor for post-cesarean endometritis.  Obstet Gynecol. 1990;  75 52-58
• 24 Meis P J, Goldenberg R L, Mercer B et al.. The Preterm Prediction Study: significance of vaginal infections.  Am J Obstet Gynecol. 1995;  173 1231-1235
• 25 Morales W J, Schorr S, Albritton J. Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study.  Am J Obstet Gynecol. 1994;  171 345-349
• 26 Hauth J C, Goldenberg R L, Andrews W W et al.. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis.  N Engl J Med. 1995;  333 1732-1735
• 27 McDonald H M, O'Loughlin J A, Vigneswaran R et al.. Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis (Gardnerella vaginalis): a randomized placebo controlled trial.  Br J Obstet Gynaecol. 1997;  104 1391-1397
• 28 Carey J C, Klebanoff M A, Hauth J C et al.. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis.  N Engl J Med. 2000;  342 534-540
• 29 Sobel J D, Schmitt C, Merriwether C. Long-term follow-up of patients with bacterial vaginosis treated with oral metronidazole and topical clindamycin.  J Infect Dis. 1993;  167 783-784
• 30 Vermeulen G M, Bruinse H W. Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial.  Br J Obstet Gynaecol. 1999;  106 652-657
• 31 Joesoef M R, Hillier S L, Wiknjosastro G et al.. Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight.  Am J Obstet Gynecol. 1995;  173 1527-1531
• 32 Kekki M, Kurki T, Pelkonen J et al.. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized controlled trial.  Obstet Gynecol. 2001;  97 643-648
• 33 Krohn M A, Thwin S S, Rabe L K et al.. Vaginal colonization by Escherichia coli as a risk factor for very low birth weight delivery and other perinatal complications.  J Infect Dis. 1997;  175 606-610
• 34 Lamont R F, Duncan SLB, Mandal D et al.. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora.  Obstet Gynecol. 2003;  101 516-522
• 35 Ugwumadu A, Manyonda I, Reid F et al.. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial.  Lancet. 2003;  361 983-988
• 36 Hoyme U B, Grosh A, Roemer V M. Initial results of the Erfurt Prevention of Prematurity Campaign.  Z Geburtshilfe Neonatol. 1998;  202 247-250
• 37 Hay P E, Morgan D J, Ison C A et al.. A longitudinal study of bacterial vaginosis during pregnancy.  Br J Obstet Gynaecol. 1994;  101 1048-1053
• 38 Hay P E, Lamont R F, Taylor-Robinson D et al.. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage.  BMJ. 1994;  308 295-298
• 39 Klebanoff M A, Hauth J C, MacPherson C A et al.. Time course of the regression of asymptomatic bacterial vaginosis in pregnancy with and without treatment.  Am J Obstet Gynecol. 2004;  190 363-370
• 40 Leitich H, Brunbauer M, Bodner-Adler B et al.. Antibiotic treatment of bacterial vaginosis in pregnancy: a meta-analysis.  Am J Obstet Gynecol. 2003;  188 752-758
• 41 Romero R, Mazor M, Wu Y K et al.. Bacterial endotoxin and tumor necrosis factor stimulate prostaglandin production by human deciduas.  Prostaglandins Leukot Essent Fatty Acids. 1989;  37 183-186
• 42 Macones G A, Parry S, Elkousy M et al.. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth.  Am J Obstet Gynecol. 2004;  190 1504-1508
• 43 Genc M R, Witkin S S, Delaney M L et al.. A disproportionate increase in IL-1β over IL-1ra in the cervicovaginal secretions of pregnant women with altered vaginal microflora correlates with preterm labor.  Am J Obstet Gynecol. 2004;  190 1191-1197
• 44 So T, Ito A, Sato T et al.. Tumor necrosis factor alpha stimulates the production of matrix metalloproteinases and plasminogen activator in cultured human chorionic cells.  Biol Reprod. 1992;  46 772-778
• 45 Yudin M H, Landers D V, Meyn L et al.. Clinical and cervical cytokine response to treatment with oral or vaginal metronidazole for bacterial vaginosis during pregnancy: a randomized trial.  Obstet Gynecol. 2003;  102 527-534
• 46 Klebanoff M A, Carey C, Hauth J C et al.. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic trichomonas vaginalis infection.  N Engl J Med. 2001;  345 487-493
• 47 Champney W S, Curtis S K, Samuels R. Cytopathology and release of an RNA virus from a strain of Trichomonas vaginalis .  Int J Parasitol. 1995;  25 1463-1471
• 48 Kigozi G G, Brahmbhatt H, Wabwire-Mangen F et al.. Treatment of Trichomonas in pregnancy and adverse outcomes of pregnancy: a subanalysis of a randomized trial in Rakai, Uganda.  Am J Obstet Gynecol. 2003;  189 1398-1400
• 49 Goldenberg R L, Mercer B M, Meis P J et al.. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth.  Obstet Gynecol. 1996;  87 643-648
• 50 Wennerholm U B, Holm B, Mattsby-Baltzer I et al.. Fetal fibronectin, endotoxin, bacterial vaginosis and cervical length as predictors of preterm birth and neonatal morbidity in twin pregnancies.  Br J Obstet Gynaecol. 1997;  104 1398-1401
• 51 Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy (Cochrane Review). Cochrane Library, issue 1. Oxford, United Kingdom; Update Software 2002
• 52 The United States Preventive Services Task Force . Screening for bacterial vaginosis in pregnancy: recommendations and rationale.  Am J Prev Med. 2001;  20 59-61
• 53 Centers for Disease Control and Prevention . 1998 Guidelines for treatment of sexually transmitted diseases.  MMWR Morb Mortal Wkly Rep. 1997;  47 , (no. RR-1)
• 54 American College of Obstetricians and Gynecologists .Assessment of risk factors for preterm birth. Practice bulletin No. 31. Washington, DC; American College of Obstetricians and Gynecologists 2001
• 55 Goldenberg R L, Klebanoff M, Carey J C et al.. Metronidazole treatment of women with a positive fetal fibronectin test result.  Am J Obstet Gynecol. 2001;  185 485-486
• 56 Johnson JWC, Austin K L, Jones G S et al.. Efficacy of 17 alpha-hydroxyprogesterone caproate in the prevention of premature labor.  N Engl J Med. 1975;  293 675-680
• 57 Hauth J C, Gilstrap L C, Brekken A L et al.. The effect of 17 α-hydroxyprogesterone caproate on pregnancy outcome in active-duty military population.  Am J Obstet Gynecol. 1983;  146 187-190
• 58 Yemini M, Borenstein R, Dreazen E et al.. Prevention of premature labor by 17 alpha-hydroxyprogesterone caproate.  Am J Obstet Gynecol. 1985;  151 574-577
• 59 Hartikainen-Sorri A, Kauppila A, Tuimala R. Inefficacy of 17 α-hydroxyprogesterone caproate in the prevention of prematurity in twin pregnancy.  Obstet Gynecol. 1980;  56 692-695
• 60 Goldstein P, Berrien J, Rosen S et al.. A meta-analysis of randomized control trials of progestational agents in pregnancy.  Br J Obstet Gynaecol. 1989;  96 265-274
• 61 Keirse M J. Progestogen administration in pregnancy may prevent preterm delivery.  Br J Obstet Gynaecol. 1990;  97 149-154
• 62 Meis P J, Klebanoff M, Thom E et al.. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.  N Engl J Med. 2003;  348 2379-2385
• 63 Da Fonseca E B, Bittar R E, Carvalho M H et al.. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study.  Am J Obstet Gynecol. 2003;  188 419-424
• 64 Fuchs A R, Fuchs F. Endocrinology of human parturition: a review.  Br J Obstet Gynaecol. 1984;  91 948-967
• 65 Challis JRG. Sharp increases in free circulating oestrogens immediately before parturition in sheep.  Nature. 1971;  229 208-210
• 66 Romero R, Scoccia B, Mazor M et al.. Evidence for a local change in the progesterone/estrogen ratio in human parturition at term.  Am J Obstet Gynecol. 1988;  159 657-661
• 67 Mazor M, Hershkovitz R, Chaim W et al.. Human preterm birth is associated with systemic and local changes in progesterone/17 beta-estradiol ratios.  Am J Obstet Gynecol. 1994;  171 231-236
• 68 Garfield R E, Kannan M S, Daniel E E. Gap junction formation in the myometrium: control by estrogens, progesterone, and prostaglandins.  Am J Physiol. 1980;  238 C81-C89
• 69 Alexandrova M, Soloff M S. Oxytocin receptors and parturition. I: control of oxytocin receptor concentration in rat myometrium at term.  Endocrinology. 1980;  106 730-735
• 70 Olson D M, Skinner K, Challis JRG. Estradiol-17 beta and 2-hydroxyestradiol-17 beta induced differential production of prostaglandins by cells dispersed from human intrauterine tissues at parturition.  Prostaglandins. 1983;  25 639-651
• 71 Schatz F, Gurpide E. Effects of estradiol on prostaglandin F2 alpha levels in primary monolayer culture of epithelial cells from human proliferative endometrium.  Endocrinology. 1983;  113 1274-1279
• 72 Chwalisz K, Fahrenholz F, Hackenberg M et al.. The progesterone antagonist onapristone increases the effectiveness of oxytocin to produce delivery without changing the myometrial oxytocin receptor concentration.  Am J Obstet Gynecol. 1991;  165 1760-1770
• 73 Critchley H O, Jones R L, Lea R G et al.. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy.  J Clin Endocrinol Metab. 1999;  84 240-248
• 74 Tibbetts T A, Conneely O M, O'Malley B W. Progesterone via its receptor antagonizes the pro-inflammatory activity of estrogen in the mouse uterus.  Biol Reprod. 1999;  60 1158-1165
• 75 Bamberger C M, Schulte H M. Molecular mechanisms of dissociative glucocorticoid activity.  Eur J Clin Invest. 2000;  30 6-9
• 76 Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine demise.  Am J Obstet Gynecol. 2004;  190 693-701
• 77 Hobel C J, Ross M G, Bemis R L et al.. The West Los Angeles Preterm Birth Prevention Project. I: program impact on high-risk women.  Am J Obstet Gynecol. 1994;  170 54-62
• 78 Hirsch E, Muhle R. Intrauterine bacterial inoculation induces labor in the mouse by mechanisms other than progesterone withdrawal.  Biol Reprod. 2002;  67 1337-1341
• 79 Resseguie L J, Hick J F, Bruen J A et al.. Congenital malformations among offspring exposed in utero to progestins, Olmsted County, Minnesota, 1936-1974.  Fertil Steril. 1985;  43 514-519
• 80 Kimmel G L, Hartwell B S, Andrew F D. A potential mechanism in medroxyprogesterone acetate teratogenesis.  Teratology. 1979;  19 171-176
• 81 Katz Z, Lancet M, Skornik J et al.. Teratogenicity of progestogens given during the first trimester of pregnancy.  Obstet Gynecol. 1985;  65 775-780
• 82 American College of Obstetricians and Gynecologists .Use of progesterone to reduce preterm birth. Committee Opinion No. 291. Washington, DC; American College of Obstetricians and Gynecologists 2003
• 83 Martin J A, Hamilton B E, Sutton P D et al.. Births: final data for 2002.  Natl Vital Stat Rep. 2003;  52 1-113
• 84 Wu Y W, Colford Jr J M. Chorioamnionitis as a risk factor for cerebral palsy: a meta-analysis.  JAMA. 2000;  284 1417-1424
• 85 Hagberg H, Wennerholm U B, Savman K. Sequelae of chorioamnionitis.  Curr Opin Infect Dis. 2002;  15 301-306